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Expression of canine IL-4 in E.coli and mammalian cells (CHO-cells/canine chondrocytes) 
and development of a direct- Sandwich-ELISA for the measurement of canine Interleukin-4 
The aim of this study was to find fitting target cells and transfection mechanisms and to develop a 
suitable method for the measurement of the canine IL-4, creating a basis for the future use of gene 
therapy with Interleukin-4 in the treatment of rheumatoid arthritis of dogs. 
The canine IL-4 was cloned in our institute and encloned in a transfection vector for mammalian 
cells (pcDNA3.1). Numerous studies proved cartilage cells to be particularly suitable as target 
cells for a transfection and for a following transplantation into the infected joint. As it was 
impossible to commercially acquire a canine cartilage cell line, in the context of this study 
primary canine cartilage cells were used. For the transfection CHO cells were used as reference 
cells. The transfection was carried out with cationic lipids (LipofectAMINE-PLUSTM). They 
allowed a high degree of transfection efficiency; at the same time the potential danger, which can 
originate in viral vectors, could be eliminated. 
For the qualitative registration of the transfection efficiency the gene for canine IL-4 was also 
encloned in a GFP plasmide with the aim to achieve a fluorescence-microscopic representation of 
the transfection. The transfection efficiency amounted to about 35 %. 
In addition the mRNA of the transfected CHO cells and cartilage cells was gained with the help 
of the TriStar reagent and proved with RT-PCR. 
For the quantitative measurement of the expression of IL-4 the double sandwich ELISA was 
developed. To reach a higher sensitivity the enforcement system Biotin/Streptavidin was applied. 
The utmost sensitivity degree amounted to 0.1 ng/ml = 5 pg protein mass. 
The measurements of IL-4 in the supernatant of the transfected cartilage cells showed that it was 
possible to gain up to 260 ng/ml expressed IL-4 from about 102 cartilage cells. 
In a further step it will have to be shown that the high expression degree of the IL-4 of the 
transfected cartilage cells is sufficient to achieve acceptable therapeutic effects in the infected 
joint. If this can be proven, a decisive step towards the development of a gene therapy against 




Gene therapy is considered to be a promising concept of treatment in many ranges. A high 
scientific interest in this method of treatment consists especially in the field of orthopaedics. The 
specifical use of the cytokine Interleukin-4, which has an anti-inflammatory effect, for the 
treatment of rheumatoid arthritis of humans is regarded as a promising approach. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
